Paper Details

  1. Home
  2. Paper Details

Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Author: NiermanPia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Acalabrutinib is a newer Bruton tyrosine kinase inhibitor (BTKi) used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). While effective, BTKi therapy can cause unique adverse events and toxicities in patients with CLL/SLL, requiring careful monitoring and management.
Paper Details　
Original Abstract of the Article :
Acalabrutinib is a next-generation Bruton tyrosine kinase inhibitor (BTKi) that has moved to the forefront of treatment options for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients with CLL/SLL can experience adverse events and toxicities unique to BTKi ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1188/21.CJON.687-696

データ提供：米国国立医学図書館（NLM）

Acalabrutinib: A New Hope for CLL and SLL

The battle against chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) is ongoing, with new treatment options constantly emerging. Acalabrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), has emerged as a promising treatment for these blood cancers. This study explores the potential benefits and side effects of acalabrutinib in patients with CLL/SLL. The researchers discuss the unique toxicities and adverse events associated with BTKi therapy, providing valuable insights for healthcare professionals.

Acalabrutinib: A Promising BTKi for CLL/SLL

Acalabrutinib has shown great promise in treating CLL/SLL. It’s a powerful tool in the fight against these cancers, but its use must be carefully managed due to the potential for adverse events. The study emphasizes the importance of understanding the specific toxicities associated with BTKi therapy to ensure safe and effective treatment for patients.

Navigating the Landscape of CLL/SLL Treatment

This study provides valuable insights into the use of acalabrutinib for CLL/SLL. The information can be used to guide treatment decisions and manage potential side effects. The study reminds us that the path to curing these cancers is paved with research and innovation.

Dr.Camel's Conclusion

This study is like finding a new oasis in the vast desert of cancer research, offering hope for patients with CLL and SLL. Acalabrutinib shows great promise but, like all treatment options, must be carefully monitored. It’s a reminder that the journey to conquer these diseases is a continuous adventure.

Date :
  1. Date Completed 2022-04-04
  2. Date Revised 2022-04-05
Further Info :

Pubmed ID

34800101

DOI: Digital Object Identifier

10.1188/21.CJON.687-696

Related Literature

Article Analysis
・Side Effects of acalabrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.